In June 2010 DiaMedica Acquired Sanomune

DiaMedica: a merger of two of Canada’s Top 10™ life science companies
 

• DiaMedica has discovered a unique and simple mechanism to treat diabetes
• Addressing this mechanism resulted in compelling pre-clinical and clinical data
• Type 1 diabetes program led by former Vice President of Research and Development at the Juvenile Diabetes Research Foundation
• Approach supported by two past presidents of the American Diabetes Association who serve on DiaMedica's Scientific Advisory Board
• Selected as a Top 10™ Life Science Company in Canada in 2007/2008 and 2008/2009 by the Ottawa Centre for Research and Innovation

• Sanomune was focused on Neurological diseases – initially Alzheimer’s
• Showed protection and proliferation of neural cells (brain cells)
• Results "Best ever seen" in Alzheimer model - stated by leading neurological research organization
• Selected as a Top 10™ Life Science Company in Canada in 2008/2009 by the Ottawa Centre for Research and Innovation